Platelet Activation in Acute Myocardial Infarction and the Rationale for Combination Therapy

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2000 Sep 12

PMID 10980904

Citations 1

Authors

N Kleiman

Affiliations

Soon will be listed here.

Abstract

Current fibrinolytic regimens fail to fully restore coronary blood flow in slightly less than 50% of patients with acute myocardial infarction. Platelet activation and aggregation may be responsible for a large proportion of these therapeutic failures. Therefore, platelet inhibition may enhance thrombolysis. Experimental and early clinical evidence suggest that glycoprotein IIb/IIIa antagonists may enhance reperfusion when combined with reduced doses of thrombolytic agents. However, the clinical benefit of combination therapy will depend on the outcomes of a number large clinical trials that are currently being performed.

Citing Articles

Nitric oxide, platelet function, myocardial infarction and reperfusion therapies.

Alonso D, Radomski M Heart Fail Rev. 2003; 8(1):47-54.

PMID: 12652159 DOI: 10.1023/a:1022194921040.

References

Coulter S, Cannon C, Ault K, Antman E, Van de Werf F, Adgey A . High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000; 101(23):2690-5. DOI: 10.1161/01.cir.101.23.2690. View

Gao S, Morser J, McLean K, Shuman M . Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase. Thromb Res. 1990; 58(4):421-33. DOI: 10.1016/0049-3848(90)90213-v. View

de Lemos J, Antman E, Gibson C, McCabe C, Giugliano R, Murphy S . Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000; 101(3):239-43. DOI: 10.1161/01.cir.101.3.239. View

Gertz S, Kragel A, Kalan J, Braunwald E, Roberts W . Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Am J Cardiol. 1990; 66(12):904-9. DOI: 10.1016/0002-9149(90)90923-o. View

Gurwitz J, Gore J, Goldberg R, Barron H, Breen T, Rundle A . Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med. 1998; 129(8):597-604. DOI: 10.7326/0003-4819-129-8-199810150-00002. View

Kleiman N, Raizner A, Jordan R, Wang A, Norton D, Mace K . Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995; 26(7):1665-71. DOI: 10.1016/0735-1097(95)00391-6. View

. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329(22):1615-22. DOI: 10.1056/NEJM199311253292204. View

. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol. 1998; 32(7):2003-10. DOI: 10.1016/s0735-1097(98)00474-4. View

. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol. 1988; 12(6 Suppl A):3A-13A. DOI: 10.1016/0735-1097(88)92635-6. View

10.

Fitzgerald D, Wright F, FitzGerald G . Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res. 1989; 65(1):83-94. DOI: 10.1161/01.res.65.1.83. View

11.

. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998; 352(9122):87-92. DOI: 10.1016/s0140-6736(98)06113-3. View

12.

. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation. 2000; 101(24):2788-94. DOI: 10.1161/01.cir.101.24.2788. View

13.

Gurbel P, Serebruany V, Shustov A, BAHR R, Carpo C, Ohman E . Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J Am Coll Cardiol. 1998; 31(7):1466-73. DOI: 10.1016/s0735-1097(98)00172-7. View

14.

Serebruany V, Gurbel P, Shustov A, Ohman E, Topol E . Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. Am Heart J. 1998; 136(3):398-405. DOI: 10.1016/s0002-8703(98)70212-1. View

15.

Woods Jr V, Wolff L, Keller D . Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem. 1986; 261(32):15242-51. View

16.

Becker , Bovill , Corrao , Ball , Ault , Mann . Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction. J Thromb Thrombolysis. 1995; 2(1):57-64. DOI: 10.1007/BF01063163. View

17.

. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985; 312(14):932-6. DOI: 10.1056/NEJM198504043121437. View

18.

Schafer A, Adelman B . Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest. 1985; 75(2):456-61. PMC: 423519. DOI: 10.1172/JCI111720. View

19.

Davies M, Thomas A, Knapman P, Hangartner J . Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation. 1986; 73(3):418-27. DOI: 10.1161/01.cir.73.3.418. View

20.

Ohman E, Califf R, Topol E, Candela R, Abbottsmith C, Ellis S . Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation. 1990; 82(3):781-91. DOI: 10.1161/01.cir.82.3.781. View